In Vitro Susceptibility of Environmental Cryptococcus neoformans Variety neoformans Isolates from Turkey to Six Antifungal Agents, Including SCH56592 and Voriconazole

2000 ◽  
Vol 19 (4) ◽  
pp. 317-319 ◽  
Author(s):  
S. T. Yildiran ◽  
M. A. Saracli ◽  
A. W. Fothergill ◽  
M. G. Rinaldi
Keyword(s):  
Cryptococcus Neoformans ◽  
Antifungal Agents ◽  
In Vitro Susceptibility

scholarly journals In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil

2001 ◽  
Vol 43 (5) ◽  
pp. 267-270 ◽  
Author(s):  
Sydney Hartz ALVES ◽  
Loiva T. OLIVEIRA ◽  
Jane M. COSTA ◽  
Irina LUBECK ◽  
Agnes Kiesling CASALI ◽  
...  
Keyword(s):  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Antifungal Agents ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Environmental Isolates ◽  
Aids Patients ◽  
In Vitro Susceptibility ◽  
Minimal Inhibitory Concentrations

The purpose of the present study was to compare the susceptibility to four antifungal agents of 69 Cryptococcus neoformans strains isolated from AIDS patients with that of 13 C. neoformans strains isolated from the environment. Based on the NCCLS M27-A methodology the Minimal Inhibitory Concentrations (MICs) obtained for amphotericin B, itraconazole and ketoconazole were very similar for clinical and environmental isolates. Clinical isolates were less susceptible to fluconazole than environmental isolates. The significance of these findings and aspects concerning the importance, role and difficulties of C. neoformans susceptibility testing are also discussed.

scholarly journals Structure and inhibition of Cryptococcus neoformans sterylglucosidase to develop antifungal agents

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nivea Pereira de Sa ◽  
Adam Taouil ◽  
Jinwoo Kim ◽  
Timothy Clement ◽  
Reece M. Hoffmann ◽  
...  
Keyword(s):  
Cryptococcus Neoformans ◽  
Rational Design ◽  
Antifungal Agents ◽  
Pathogenic Fungus ◽  
Pathogenic Fungi ◽  
Growth Defect ◽  
Wild Type ◽  
Secondary Infections ◽  
Heavy Burden

AbstractPathogenic fungi exhibit a heavy burden on medical care and new therapies are needed. Here, we develop the fungal specific enzyme sterylglucosidase 1 (Sgl1) as a therapeutic target. Sgl1 converts the immunomodulatory glycolipid ergosterol 3β-D-glucoside to ergosterol and glucose. Previously, we found that genetic deletion of Sgl1 in the pathogenic fungus Cryptococcus neoformans (Cn) results in ergosterol 3β-D-glucoside accumulation, renders Cn non-pathogenic, and immunizes mice against secondary infections by wild-type Cn, even in condition of CD4+ T cell deficiency. Here, we disclose two distinct chemical classes that inhibit Sgl1 function in vitro and in Cn cells. Pharmacological inhibition of Sgl1 phenocopies a growth defect of the Cn Δsgl1 mutant and prevents dissemination of wild-type Cn to the brain in a mouse model of infection. Crystal structures of Sgl1 alone and with inhibitors explain Sgl1’s substrate specificity and enable the rational design of antifungal agents targeting Sgl1.

scholarly journals In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates

1998 ◽  
Vol 42 (2) ◽  
pp. 471-472 ◽  
Author(s):  
M. Hong Nguyen ◽  
Christine Y. Yu
Keyword(s):  
Cryptococcus Neoformans ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Comparative Efficacy ◽  
In Vitro Susceptibility ◽  
In Vitro Susceptibility Testing ◽  
Fluconazole Resistant ◽  
Dose Dependent

ABSTRACT In vitro susceptibility testing for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole. Voriconazole was more potent than itraconazole for fluconazole-susceptible isolates and as potent as itraconazole for fluconazole-susceptible dose-dependent isolates and for fluconazole-resistant isolates. For fluconazole-resistant isolates, the voriconazole and itraconazole MICs ranged from 1 to 2 μg/ml.

In vitro susceptibility of dematiaceous fungi to nine antifungal agents determined by two different methods

Mycoses ◽  
2019 ◽  
Vol 62 (4) ◽  
pp. 384-390 ◽  
Author(s):  
Hailin Zheng ◽  
Yun He ◽  
Siyue Kan ◽  
Dongmei Li ◽  
Guixia Lv ◽  
...  
Keyword(s):  
Antifungal Agents ◽  
Dematiaceous Fungi ◽  
In Vitro Susceptibility

scholarly journals Current and Emerging Azole Antifungal Agents

1999 ◽  
Vol 12 (1) ◽  
pp. 40-79 ◽  
Author(s):  
Daniel J. Sheehan ◽  
Christopher A. Hitchcock ◽  
Carol M. Sibley
Keyword(s):  
Fungal Pathogens ◽  
Antifungal Agents ◽  
Susceptibility Testing ◽  
Fungal Infections ◽  
Mechanisms Of Action ◽  
Current Status ◽  
In Vitro Susceptibility ◽  
Clinical Resistance ◽  
In Vitro Susceptibility Testing

SUMMARY Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.

scholarly journals In Vitro Susceptibility of Thai Pythium insidiosum Isolates to Antibacterial Agents

2020 ◽  
Vol 64 (4) ◽  
Author(s):  
Navaporn Worasilchai ◽  
Ariya Chindamporn ◽  
Rongpong Plongla ◽  
Pattama Torvorapanit ◽  
Kasama Manothummetha ◽  
...  
Keyword(s):  
Antibacterial Agents ◽  
Antifungal Agents ◽  
Radical Surgery ◽  
Synergistic Effects ◽  
In Vitro Susceptibility ◽  
Pythium Insidiosum ◽  
Content Type ◽  
Life Threatening ◽  
Report Data

ABSTRACT Human pythiosis is a life-threatening human disease caused by Pythium insidiosum. In Thailand, vascular pythiosis is the most common form and carries a mortality rate of 10 to 40%, despite aggressive treatment with radical surgery, antifungal agents, and immunotherapy. Itraconazole and terbinafine have been the mainstay of treatment, until recently, based on case report data showing potential synergistic effects against Brazilian P. insidiosum isolates. However, the synergistic effects of itraconazole and terbinafine against Thai P. insidiosum isolates were not observed. This study tested the in vitro susceptibilities of 27 Thai human P. insidiosum isolates (clade II, n = 17; clade IV, n = 10), 12 Thai environmental P. insidiosum isolates (clade II, n = 4; clade IV, n = 8), and 11 non-Thai animal P. insidiosum isolates (clade I, n = 9; clade II, n = 2) to antibiotics in eight antibacterial classes to evaluate alternative effective treatments. Tetracycline and macrolide antibiotics demonstrated in vitro activity against Thai P. insidiosum isolates, with doxycycline MICs (1 to 16 μg/ml), minocycline MICs (1 to 4 μg/ml), tigecycline MICs (1 to 4 μg/ml), azithromycin MICs (1 to 16 μg/ml), and clarithromycin MICs (0.125 to 8 μg/ml) being the lowest, on average. Synergistic effects of tetracyclines and macrolides were also observed.

Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south‐eastern Brazil

Mycoses ◽  
2020 ◽  
Vol 63 (12) ◽  
pp. 1341-1351
Author(s):  
Patrícia Helena Grizante Barião ◽  
Ludmilla Tonani ◽  
Tiago Alexandre Cocio ◽  
Roberto Martinez ◽  
Érika Nascimento ◽  
...  
Keyword(s):  
Cryptococcus Neoformans ◽  
Molecular Typing ◽  
Species Complex ◽  
Cryptococcus Gattii ◽  
Clinical Isolates ◽  
In Vitro Susceptibility ◽  
South Eastern ◽  
Eastern Brazil

scholarly journals New sulfone and sulfanyl derivatives with antifungal activity

2018 ◽  
pp. 175-184
Author(s):  
Małgorzata Gizińska ◽  
Marzena Połaska ◽  
Zbigniew Ochal ◽  
Monika Staniszewska
Keyword(s):  
Antifungal Agents ◽  
Fungal Infections ◽  
In Vitro Susceptibility ◽  
Microdilution Method ◽  
Alternative Approach ◽  
Broth Microdilution Method ◽  
Fungal Morphogenesis ◽  
In Vitro Susceptibility Testing ◽  
Base Structure

Introduction: Increasing occurrence of fungal infections raises the need to develop novel antifungal agents. In this context, an inhibition of morphological switch may provide an alternative approach to find compounds with a potential to control the Candida albicans infections. Methods: A series of 17 sulfone and sulfanyl derivatives was synthesized and evaluated for activity against the C. albicans wild type (SC5314, ATCC) and SAP-deficient mutant strains using the broth microdilution method M27-A3. Afterwards, phase-contrast microscopy was applied to evaluate the inhibition of fungal morphogenesis under the influence of randomly selected active compounds: 1, 5 and 6. Results: By in vitro susceptibility testing of C. albicans, we identified the effective antifungal agents displaying moderate-to-good activity. Newly synthesized sulfanyl and sulfone derivatives strongly inhibited the C. albicans morphogenetic transition under the hyphae inducing conditions. Conclusions: The leading compound 6 has the potential to be used as a base structure in antifungal drug development, however further structural optimalization and toxicity studies are required.

Sign in / Sign up

Export Citation Format

Share Document